- In January 2025, Illumina, Inc., a leader in genomics, announced the launch of its new NovaSeq 6000 System, designed to enhance sequencing performance with improved throughput and accuracy for genomic research. The system leverages advanced technology to accelerate the pace of genomic discovery, enabling faster and more cost-effective sequencing for applications such as personalized medicine, cancer research, and genetic disease diagnostics. The NovaSeq 6000's scalable design offers unmatched flexibility, making it ideal for a broad range of research needs from clinical diagnostics to large-scale genome studies
- In October 2024, Thermo Fisher Scientific presented new developments at the American Society of Human Genetics (ASHG) 2024 conference, including the release of its Ion Proton System, which offers high-throughput next-generation sequencing (NGS) capabilities for precision medicine. This new technology aims to reduce sequencing costs and improve turnaround times, enabling faster clinical diagnostics and more accurate genomic profiling for patients with inherited genetic disorders
- In September 2024, Qiagen N.V. announced the launch of its new QIAseq Targeted RNA Panels for precision oncology. The panels, designed for accurate and efficient RNA sequencing, will help researchers and clinicians identify genetic mutations and biomarkers in cancer patients, improving the ability to make informed treatment decisions based on genetic profiles. These panels offer higher sensitivity and better coverage, ensuring reliable results even from challenging and low-input samples
- In September 2024, Oxford Nanopore Technologies unveiled its GridION X5, a new benchtop device that allows for high-throughput sequencing with real-time results. The GridION X5 offers genomic researchers the flexibility to perform sequencing in a variety of applications, from large-scale genomic studies to point-of-care diagnostics. The system features improved data accuracy and scalability, allowing researchers to adapt their workflows to meet the growing demand for genomic testing and analysis
